Journal
JOURNAL OF CHILD NEUROLOGY
Volume 34, Issue 2, Pages 74-80Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/0883073818811223
Keywords
intellectual disability; leukodystrophy; neurodevelopment; spasticity; seizures
Categories
Funding
- Genome Canada
- Canadian Institutes of Health Research
- Ontario Genomics Institute
- Ontario Research Fund
- Genome Quebec
- Children's Hospital of Eastern Ontario Foundation
- Fondation Leuco Dystrophie
- Fondation les Amis d'Eliott
- Fondation Lueur d'Espoir pour Ayden
- Reseau de Medecine Genetique Appliquee
Ask authors/readers for more resources
AIMP1/p43, is a noncatalytic component of the mammalian multi-tRNA synthetase complex that catalyzes the ligation of amino acids to their cognate tRNAs. AIMP1 is largely expressed in the central nervous system, where it is part of the regulatory machine of the neurofilament assembly, playing a crucial role in neuronal development and function. To date, nonsense mutations in AIMP1 have been associated with a primary neurodegenerative disorder consisting of cerebral atrophy, hypomyelination, microcephaly and epilepsy, whereas missense mutations have recently been linked to intellectual disability without neurodegeneration. Here, we report the first French-Canadian patient with a novel frameshift AIMP1 homozygous mutation (c.191_192delAA, p.Gln64Argfs*25), resulting in a severe neurodegenerative phenotype. We review and discuss the phenotypic spectrum associated with AIMP1 pathogenic variants.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available